Inflectra (Infliximab)

Infliximab is a monoclonal antibody that binds specifically to both soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By neutralizing TNF‑α, it interrupts the cascade of pro‑inflammatory signals that drive autoimmune inflammation, thereby reducing tissue damage and clinical signs of disease.

The dosing regimen for Inflectra is individualized and determined by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, and response to therapy. Physicians follow approved labeling and clinical guidelines to set the infusion schedule and amount.

Data on the use of infliximab during pregnancy and lactation are limited. The drug crosses the placenta, especially in the third trimester, and may be present in breast milk. Clinicians weigh potential benefits against risks and generally reserve use for situations where no safer alternatives exist.

To request Inflectra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Inflectra is a biosimilar to the reference product Remicade (infliximab). Clinical studies have demonstrated comparable efficacy, safety, and immunogenicity. Compared with other TNF‑alpha inhibitors such as adalimumab or etanercept, infliximab is administered intravenously, allowing controlled dosing in a clinical setting.

Inflectra must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken. Prior to infusion, the product is allowed to reach room temperature as directed by the prescribing information.

Inflectra is given as an intravenous infusion in a healthcare facility. The initial dose is usually administered over a period of 2 hours, followed by subsequent infusions at intervals recommended for the specific indication, such as every 6 to 8 weeks for rheumatoid arthritis.

Serious risks include severe infections (including tuberculosis and opportunistic pathogens), reactivation of latent TB, demyelinating diseases, heart failure exacerbation, and rare malignancies. Patients should be monitored closely for signs of infection, neurological changes, or cardiac symptoms throughout therapy.

Inflectra is contraindicated in individuals with known hypersensitivity to infliximab or any component of the formulation, and in patients with active serious infections, including untreated tuberculosis. Caution is also advised for those with moderate to severe heart failure or a history of demyelinating disorders.